BRPI1012203A2 - derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 - Google Patents
derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1Info
- Publication number
- BRPI1012203A2 BRPI1012203A2 BRPI1012203A BRPI1012203A BRPI1012203A2 BR PI1012203 A2 BRPI1012203 A2 BR PI1012203A2 BR PI1012203 A BRPI1012203 A BR PI1012203A BR PI1012203 A BRPI1012203 A BR PI1012203A BR PI1012203 A2 BRPI1012203 A2 BR PI1012203A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyp11b1
- indol
- pyridin
- modulators
- dihydro
- Prior art date
Links
- LRXSVYIRRDZVNQ-UHFFFAOYSA-N 5-pyridin-3-yl-1,3-dihydroindol-2-one Chemical class C=1C=C2NC(=O)CC2=CC=1C1=CC=CN=C1 LRXSVYIRRDZVNQ-UHFFFAOYSA-N 0.000 title 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 title 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 title 1
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17868409P | 2009-05-15 | 2009-05-15 | |
| US32721810P | 2010-04-23 | 2010-04-23 | |
| PCT/EP2010/056569 WO2010130794A1 (en) | 2009-05-15 | 2010-05-12 | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012203A2 true BRPI1012203A2 (pt) | 2016-04-05 |
Family
ID=42342893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012203A BRPI1012203A2 (pt) | 2009-05-15 | 2010-05-12 | derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8778972B2 (pt) |
| EP (1) | EP2430011A1 (pt) |
| JP (1) | JP2015034187A (pt) |
| KR (1) | KR20120023091A (pt) |
| CN (1) | CN102459223B (pt) |
| AU (1) | AU2010247412A1 (pt) |
| BR (1) | BRPI1012203A2 (pt) |
| CA (1) | CA2761858A1 (pt) |
| EA (1) | EA201101619A1 (pt) |
| MX (1) | MX2011012202A (pt) |
| WO (1) | WO2010130794A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| EA021464B1 (ru) * | 2008-01-22 | 2015-06-30 | Вернэлис (Р&Д) Лтд. | Производные индол-пиридона, обладающие ингибиторной активностью в отношении киназы 1, содержащая их фармацевтическая композиция и их применение |
| BRPI1012203A2 (pt) | 2009-05-15 | 2016-04-05 | Novartis Ag | derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 |
| EP2430018B1 (en) | 2009-05-15 | 2013-07-03 | Novartis AG | Benzoxazolone derivatives as aldosterone symthase inhibitors |
| ES2551002T3 (es) | 2009-11-17 | 2015-11-13 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
| JP6263469B2 (ja) * | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
| SG11201402199QA (en) * | 2011-11-30 | 2014-09-26 | Hoffmann La Roche | New bicyclic dihydroisoquinoline-1-one derivatives |
| SI2838883T1 (en) * | 2012-04-17 | 2018-02-28 | F. Hoffmann-La Roche Ag | New derivatives of phenyl-tetrahydroisoquinoline |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| AU2014282769A1 (en) | 2013-06-21 | 2015-12-17 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| CN104530000B (zh) * | 2014-12-12 | 2016-07-20 | 重庆博腾制药科技股份有限公司 | 一种醛固酮合酶调节剂中间体的制备方法 |
| CN104496885B (zh) * | 2015-01-12 | 2017-08-25 | 中国药科大学 | 一种n‑甲基‑4‑氨基‑5‑硝基靛红的制备方法 |
| EA201992142A1 (ru) | 2017-03-10 | 2020-04-07 | Эмбера Неуротерапеутикс, Инк. | Фармацевтические композиции и их применения |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| CN111315735B (zh) * | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| CN111936490A (zh) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| EP3768267B1 (en) | 2018-03-20 | 2025-05-14 | Icahn School of Medicine at Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| WO2020142485A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN113557235B (zh) | 2019-03-06 | 2025-08-08 | C4医药公司 | 用于药物治疗的杂环化合物 |
| TW202535378A (zh) * | 2023-12-22 | 2025-09-16 | 大陸商上海翊石醫藥科技有限公司 | 一種芳雜環化合物及其製備方法和應用 |
| WO2025261526A1 (zh) * | 2024-06-21 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 双稠环类化合物、及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE425142T1 (de) | 1999-04-23 | 2009-03-15 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| US9259390B2 (en) | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| GT200600179A (es) | 2005-04-29 | 2006-11-22 | Proceso para preparar oxindoles y tio-oxindoles 3,3-disustituidos | |
| PE20070220A1 (es) | 2005-07-29 | 2007-03-19 | Wyeth Corp | Proceso para la sintesis de moduladores del receptor de progesterona |
| KR20080037070A (ko) | 2005-08-25 | 2008-04-29 | 쉐링 코포레이션 | 알파２ｃ 아드레날린성 수용체 효능제 |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| EP2430018B1 (en) | 2009-05-15 | 2013-07-03 | Novartis AG | Benzoxazolone derivatives as aldosterone symthase inhibitors |
| SI2429995T1 (sl) | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
| BRPI1012203A2 (pt) | 2009-05-15 | 2016-04-05 | Novartis Ag | derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 |
-
2010
- 2010-05-12 BR BRPI1012203A patent/BRPI1012203A2/pt not_active Application Discontinuation
- 2010-05-12 AU AU2010247412A patent/AU2010247412A1/en not_active Abandoned
- 2010-05-12 MX MX2011012202A patent/MX2011012202A/es not_active Application Discontinuation
- 2010-05-12 US US13/319,786 patent/US8778972B2/en not_active Expired - Fee Related
- 2010-05-12 EP EP20100720405 patent/EP2430011A1/en not_active Withdrawn
- 2010-05-12 KR KR1020117029905A patent/KR20120023091A/ko not_active Withdrawn
- 2010-05-12 CN CN201080031284.0A patent/CN102459223B/zh not_active Expired - Fee Related
- 2010-05-12 EA EA201101619A patent/EA201101619A1/ru unknown
- 2010-05-12 CA CA2761858A patent/CA2761858A1/en not_active Abandoned
- 2010-05-12 WO PCT/EP2010/056569 patent/WO2010130794A1/en not_active Ceased
-
2014
- 2014-05-30 US US14/291,053 patent/US20140275175A1/en not_active Abandoned
- 2014-11-20 JP JP2014235572A patent/JP2015034187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102459223B (zh) | 2014-11-05 |
| KR20120023091A (ko) | 2012-03-12 |
| EA201101619A1 (ru) | 2012-05-30 |
| US20120071512A1 (en) | 2012-03-22 |
| CA2761858A1 (en) | 2010-11-18 |
| US20140275175A1 (en) | 2014-09-18 |
| AU2010247412A1 (en) | 2011-11-24 |
| JP5654573B2 (ja) | 2015-01-14 |
| JP2012526773A (ja) | 2012-11-01 |
| US8778972B2 (en) | 2014-07-15 |
| CN102459223A (zh) | 2012-05-16 |
| JP2015034187A (ja) | 2015-02-19 |
| WO2010130794A1 (en) | 2010-11-18 |
| MX2011012202A (es) | 2011-12-08 |
| EP2430011A1 (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012203A2 (pt) | derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 | |
| PT2513105E (pt) | Derivados de 2-arilimidazole como inibidores da enzima pde10a | |
| BR112012008074A2 (pt) | derivados de piridina e pirazina como moduladores de proteína quinase | |
| BRPI0914223A2 (pt) | derivados de tiofeno ou tiazol e seus usos como inibidores de p13k | |
| BR112013015234A2 (pt) | derivados fosforosos como moduladores de receptor de quimiocina | |
| BRPI0910439A2 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk) | |
| EP2280954B8 (en) | 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2 | |
| BR112013014314A2 (pt) | derivados de 6-amino-2-fenilamino-1h-benzimidazol-5-carboxamida e seu uso como inibidores de prostaglandina e2 sintase-1 microssômicas | |
| BRPI0810679A2 (pt) | Derivados de 4-aza indol e seu uso como fungicidas | |
| BRPI1010600A2 (pt) | aril piridina como inibidores de aldosterona sintase | |
| BRPI1010831A2 (pt) | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 | |
| BRPI0910832A2 (pt) | Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk) | |
| BRPI0815135A2 (pt) | Derivados de azepina como inibidores de gama secretase. | |
| BR112012013175A2 (pt) | 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2 | |
| BRPI1015038A2 (pt) | derivados espiro azacíclicos como inibidores de hsl | |
| BRPI0915867A2 (pt) | 4-fenoximetilpiperidinas como moduladores de atividade de gpr119 | |
| BRPI0919322A2 (pt) | derivados de glicosideo e usos dos mesmos como inibidores sglt | |
| BR112012003089A2 (pt) | ligação covalente reversível de moléculas funcionais | |
| BRPI0918128A2 (pt) | derivados de heterozril amida e seu uso como ativadores de glicocinase | |
| BRPI1012870A2 (pt) | derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostéricos positivos de recpetores de mglur2 | |
| BRPI0821836A2 (pt) | Indóis macrocíclicos como inibidores do vírus da hepatite c | |
| BRPI0906625A2 (pt) | Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace) | |
| BRPI0911682A2 (pt) | indóis como moduladores do recpetor da acetilcolina nicotínico subtipo alfa-71 | |
| BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |